Showing 3 posts of 3 posts found.

AstraZeneca halts lung cancer trials amidst safety concerns

October 13, 2015
Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer

AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …


AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015
Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

MedImmune building Cambridge

MedImmune and Mirati to partner on lung cancer combo

August 6, 2015
Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …

Latest content